You just read:

Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection

News provided by

Rebiotix Inc.

Aug 07, 2017, 08:02 ET